CompanyPROKNasdaqWinston-Salem, NC

Prokidney

ProKidney develops rilparencel, an autologous cell therapy for chronic kidney disease with advanced therapy designation, currently in Phase 3 testing for patients with advanced CKD and type 2 diabetes.

Stories only

SEC EDGAR ClinicalTrials.gov prokidney.com

SCHEDULE 13G/AAug 12Latest SEC filing

Aug 10Latest story

August 2026

ProKidney finishes enrollment for accelerated approval analysis in Phase 3 kidney disease trial

Aug 10Quarterly updateProkidney